Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.

Kantarjian, H M

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar 1992 - 398-405 p. digital

Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.

0732-183X

10.1200/JCO.1992.10.3.398 doi


Adult
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Blast Crisis--drug therapy
Bone Marrow Diseases--chemically induced
Cytarabine--administration & dosage
Daunorubicin--administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor--therapeutic use
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Leukemia, Myeloid, Accelerated Phase--drug therapy
Middle Aged
Prognosis
Remission Induction
Survival Analysis